With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why breast cancer survivors don't take their medicine, and what can be done about it.

2.

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

3.

FDA Approves New Drug Combo for RR Multiple Myeloma

4.

Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot